Meblanios is an Aztreonam and Avibactam injection containing Aztreonam 1500 mg and Avibactam 500 mg. Developed by AIONIOS Pharma, Meblanios is a combination product relevant to the management of selected difficult-to-treat Gram-negative bacterial infections and antimicrobial resistance.
Meblanios combines the antibacterial activity of Aztreonam with the beta-lactamase inhibitory activity of Avibactam. Understanding the role of each component is important when considering the relationship between Meblanios, Aztreonam Avibactam, beta-lactamase-mediated resistance and MBL-associated resistance.
What is Meblanios?
Meblanios is an injectable Aztreonam and Avibactam combination.
The product contains:
| Product information | Details |
|---|---|
| Brand name | Meblanios |
| Dosage form | Injection |
| Active components | Aztreonam + Avibactam |
| Aztreonam strength | 1500 mg |
| Avibactam strength | 500 mg |
| Combination | Aztreonam and Avibactam |
| Manufacturer/Company | AIONIOS Pharma |
Meblanios belongs to the broader therapeutic discussion surrounding Aztreonam Avibactam Injection, particularly in the context of difficult-to-treat Gram-negative bacterial infections and complex antimicrobial resistance.
Meblanios Composition
Each Meblanios formulation contains two active components:
Aztreonam – 1500 mg
Aztreonam is a monobactam beta-lactam antibiotic. It provides the antibacterial component of the combination and has a relevant role when discussing bacteria producing certain beta-lactamases, including metallo-beta-lactamases.
Avibactam – 500 mg
Avibactam is a beta-lactamase inhibitor. It inhibits several susceptible serine beta-lactamases and can help protect the activity of its partner beta-lactam antibiotic from enzymatic degradation.
Importantly, Avibactam does not directly inhibit metallo-beta-lactamases (MBLs). The relevance of the Aztreonam and Avibactam combination comes from the complementary properties of the two components.
Meblanios and Aztreonam Avibactam
The relationship between the product and the active combination can be understood simply:
Meblanios → Brand/Product
Aztreonam + Avibactam → Active combination
Therefore, searches for terms such as Meblanios Injection, Meblanios Aztreonam Avibactam, Aztreonam Avibactam Injection and Aztreonam 1500 mg + Avibactam 500 mg Injection all relate to the same product-combination context.
This distinction also helps healthcare professionals and researchers differentiate the brand/product name from the generic combination of active components.
How Does Meblanios Work?
Meblanios combines two components with different but complementary roles.
Aztreonam provides antibacterial activity by targeting bacterial cell-wall synthesis.
Avibactam inhibits several susceptible beta-lactamases that can otherwise degrade susceptible beta-lactam antibiotics.
Some resistant Gram-negative bacteria may produce multiple beta-lactamases simultaneously. In these situations, understanding the specific resistance mechanism is important when evaluating antimicrobial treatment options.
Meblanios should therefore not be described simply as an “MBL inhibitor.” Rather, its relevance in MBL-associated resistance is related to the combination of Aztreonam’s relative stability against MBL-mediated hydrolysis and Avibactam’s inhibition of certain accompanying serine beta-lactamases.
Meblanios and MBL Resistance
Metallo-beta-lactamases, or MBLs, are important mechanisms of beta-lactam resistance in Gram-negative bacteria.
Examples include:
- NDM
- VIM
- IMP
These enzymes can hydrolyze many beta-lactam antibiotics and may occur together with other resistance mechanisms.
The Aztreonam and Avibactam combination is therefore an important subject in discussions around MBL-producing Gram-negative bacteria.
However, the presence of an MBL does not automatically determine whether a particular antibiotic combination will be appropriate. The organism, resistance mechanism, antimicrobial susceptibility results, infection site and clinical circumstances all need to be considered.
Meblanios for Difficult-to-Treat Gram-Negative Infections
Antimicrobial resistance can make some Gram-negative bacterial infections difficult to manage.
Resistance may involve:
- Beta-lactamase production
- Metallo-beta-lactamase production
- Changes in antibiotic targets
- Reduced membrane permeability
- Increased efflux
- Multiple resistance mechanisms occurring together
Meblanios is relevant to this area because it combines Aztreonam and Avibactam, two components with different roles in addressing beta-lactam resistance mechanisms.
The appropriate use of any antibacterial medicine should be based on the applicable product information, microbiological testing and professional clinical judgment.
Why Susceptibility Testing Matters
Antimicrobial susceptibility testing can provide important information about whether a bacterial isolate is susceptible to a particular antimicrobial agent.
This is especially relevant for resistant Gram-negative bacteria because resistance mechanisms can differ substantially between bacterial isolates.
For infections involving suspected MBL production or other complex resistance mechanisms, healthcare professionals may consider:
- Identification of the causative organism
- Resistance mechanism
- Antimicrobial susceptibility results
- Infection site
- Severity of infection
- Patient-specific factors
- Applicable clinical guidelines
Meblanios should not be considered a universal treatment for every resistant bacterial infection.
Meblanios Injection: Key Product Information
| Feature | Information |
|---|---|
| Brand | Meblanios |
| Dosage form | Injection |
| Active combination | Aztreonam + Avibactam |
| Aztreonam | 1500 mg |
| Avibactam | 500 mg |
| Antibacterial component | Aztreonam |
| Beta-lactamase inhibitor | Avibactam |
| Relevant resistance context | Beta-lactamase and MBL-associated resistance |
| Company | AIONIOS Pharma |
Meblanios Uses
The appropriate Meblanios uses depend on the approved product information and the clinical circumstances of the patient.
Healthcare professionals may consider factors such as:
- The identified bacterial pathogen
- Antimicrobial susceptibility results
- The resistance mechanism
- Site and severity of infection
- Renal and other patient-specific considerations
- Current antimicrobial treatment guidance
Because antibiotic selection is patient- and infection-specific, Meblanios should be administered only under appropriate healthcare-professional supervision and according to applicable prescribing information.
Meblanios and Antibiotic Resistance
Antibiotic resistance is a major challenge in the treatment of bacterial infections.
Gram-negative bacteria can acquire resistance through several mechanisms, including production of beta-lactamases and MBLs.
The combination of Aztreonam and Avibactam is scientifically important because the two components address different aspects of beta-lactam resistance.
This makes Meblanios Aztreonam Avibactam a relevant product combination in discussions surrounding antimicrobial resistance and difficult-to-treat Gram-negative bacteria.
Frequently Asked Questions About Meblanios
What is Meblanios?
Meblanios is an injectable combination containing Aztreonam 1500 mg and Avibactam 500 mg from AIONIOS Pharma.
What does Meblanios contain?
Meblanios contains:
- Aztreonam 1500 mg
- Avibactam 500 mg
Is Meblanios an Aztreonam Avibactam injection?
Yes. Meblanios is an injectable Aztreonam and Avibactam combination.
What is the role of Aztreonam in Meblanios?
Aztreonam is the antibacterial component. It is a monobactam beta-lactam antibiotic with relative stability against hydrolysis by metallo-beta-lactamases.
What is the role of Avibactam?
Avibactam is a beta-lactamase inhibitor that inhibits several susceptible serine beta-lactamases.
Does Avibactam directly inhibit MBLs?
No. Avibactam does not directly inhibit metallo-beta-lactamases.
Is Meblanios suitable for every bacterial infection?
No. Appropriate antibiotic selection depends on the organism, susceptibility testing, infection characteristics, resistance mechanism and clinical assessment.
Is Meblanios an antibiotic?
Meblanios is an injectable combination containing Aztreonam, an antibacterial agent, and Avibactam, a beta-lactamase inhibitor.
Meblanios and AIONIOS Pharma
Meblanios is an AIONIOS Pharma product containing Aztreonam and Avibactam for injection.
The product is positioned within AIONIOS Pharma’s critical-care and antimicrobial product portfolio. The company page currently identifies Meblanios as an Aztreonam & Avibactam injection containing 1500 mg + 500 mg.
For product-specific information regarding formulation, administration, storage and prescribing requirements, healthcare professionals should refer to the applicable official product documentation.
Important Medical Information
Meblanios is a prescription injectable antibacterial product and should be used under the supervision of a qualified healthcare professional.
Treatment decisions should consider the causative organism, antimicrobial susceptibility testing, infection site, severity, patient-specific factors and applicable prescribing information.
This page is provided for educational and product-information purposes and does not replace professional medical advice, prescribing information or antimicrobial susceptibility testing.